Immuno-PET developer ImaginAb has signed an exclusive license with DongCheng Pharmaceutical Group to commercialize cancer imaging radiotracers across China.
ImaginAb's radiotracer candidate zirconium-89-labeled minibody (Zr-89 Df-Crefmirlimab) aims to bind to human CD8 T-cell receptors for quantitative PET imaging of tumors in cancer patients. Initially, it will be used in third-party clinical trials, with the goal of obtaining market authorization in the country.
Under the terms of the license, ImaginAb will receive a license fee and be entitled to receive potential milestone payments and double-digit royalties on its CD8 immuno-PET product. No other details were disclosed.
